title: [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
abstract: Treatment for cancer may cause gonadal dysfunction and bone loss (cancer treatment-induced bone loss ; CTIBL) . Especially, endocrine therapies for breast cancer or prostate cancer carry a significant risk of CTIBL. Therapy-induced premature menopause in premenopausal breast cancer patients, aromatase inhibitor in postmenopausal breast cancer patients, and LHRH agonist with or without anti-androgen in prostate cancer patients may cause bone loss of 5% or more. RANKL (receptor activator of nuclear factor-κB ligand) antibody (denosumab) is effective for prevention of CTIBL and it may prevent CTIBL-induced fracture. During cancer treatment with gonadal dysfunction, bone mineral density should be carefully followed to avoid QOL impairment due to osoteoporosis.
authors.affiliation: Cancer Chemotherapy Center and Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan.
authors.forename: Shunji
authors.initials: S
authors.lastname: Takahashi
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000009:adverse effects; D000069448:Denosumab; D050723:Fractures, Bone / Q000517:prevention & control; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D017273:Goserelin / Q000009:adverse effects; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D053245:RANK Ligand / Q000276:immunology* / Q000502:physiology / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects
chemical_list: D000726:Androgen Antagonists; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D053245:RANK Ligand; D020845:Selective Estrogen Receptor Modulators; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D000069448:Denosumab; D016729:Leuprolide